News

'Yield curve tsunami' means a painful rise in U.S. government's cost of capital
It was last week's surge in long-term Treasury yields -- the rate on the 30-year T-bond saw its biggest weekly jump since ...
Apple hasn’t gotten an ‘all clear’ on tariffs, but its stock is still surging
While Trump promises new tariffs for tech products, Apple seems to have avoided the worst-case scenario, as smartphones are ...
This is America’s ‘magic number’ for retirement – and it’s lower this year
The “magic number” Americans think they need to retire comfortably dropped to $1.26 million, down $200,000 from last year’s ...
Wegovy, Zepbound makers’ stocks rally as a weight-loss-drug competitor drops out
Pfizer’s announcement that it will stop developing its oral weight-loss drug gave shares of Wegovy maker Novo Nordisk and ...
Apple Shares Advance After Wild Weekend of Tariff News
Apple investors just endured what Wedbush analyst Dan Ives is calling a "Twilight Zone weekend" of nonstop tariff news. The Trump administration said on Friday evening that computers, tablets, Apple ...
OPEC cuts forecasts for growth in oil demand, citing tariffs
The Organization of the Petroleum Exporting Countries, or OPEC, on Monday cut its forecast for growth in crude demand this year and in 2026, citing the impact of U.S. tariffs. OPEC now sees global ...
Inhibikase Names McIntyre Finance Chief as Lees-Rolfe Resigns
Inhibikase Therapeutics' chief financial officer, Garth Lees-Rolfe, has resigned from the clinical-stage pharmaceutical company, which has hired David McIntyre as its new finance chief.